Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Stephanie S. Okey, M.S. has served in various positions of increasing responsibility in the biopharmaceutical industry for over 25 years.   She began her career at Bristol Myers Squibb in 1986, then over 7 years at Genentech, Inc., followed by 19 years at Genzyme, A Sanofi Company.  Ms. Okey’s management experience during her tenure at Genyzme included serving as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases from August, 2012 to July, 2015 and as Vice President and General Manager, U.S. Genetic Diseases Business Unit from September, 2011 to August, 2012.  She has extensive launch and commercialization experience with nine rare and orphan disease therapeutics; two with REMS designation, and four large market therapeutic agents.  Ms. Okey’s specific expertise is in bringing therapeutic agents to health care providers, health care stakeholders and patients in a patient centric business model.  Ms. Okey retired from Genzyme, A Sanofi Company, in July, 2015.  In addition, she previously served as a member of the Board of the California Life Sciences Association from October, 2014 to January, 2016.  Ms. Okey holds a B.S. in Zoology from The Ohio State University and a M.S. in Immunology and Medical Microbiology from Wright State University.

Team members

Ron Cooper

President and Chief Executive Officer

Martha (Muffy) Carter

Chief Regulatory Officer

Jason Duncan

General Counsel

Per-Göran Gillberg, Ph.D., Prof.

Vice President, Development and Co-Founder

Jan Mattsson, Ph.D.

Chief Operating Officer and Co-Founder

Simon Harford

Chief Financial Officer

Patrick Horn, M.D., Ph.D.

Chief Medical Officer

Kristina Torfgård, Ph.D.

Vice President, Global Project Head